Introduction

Background
Stimulation using granulocyte growth factors associated or not to chemotherapy, is broadly used as a method in the mobilization of hematopoietic progenitor cells (HPC) from bone marrow or peripheral blood. This technique has been widely used for over two decades since the papers of Haas and Siena et al. (1) (2) (3) (4) Hematopoietic progenitor cells express the CD34 molecule on their surface, allowing their identification and quantification by flow cytometry in peripheral blood, thus determining the optimal time for their harvest by leukapheresis.
In the setting of an autologous stem cell transplantation (ASCT) program, stem cell mobilization and harvest must be reproducible. The goal is to obtain the required number of cells to ensure bone marrow engraftment, with the lowest growth factor dose and minimizing the number of leukapheresis.
The success of mobilization not only depends on the characteristics and growth factor dose, but also on patient characteristics (age and personal background) as well as on the underlying disorder (disease extension, chemotherapy and/or radiotherapy burden and intensity).
Different granulocyte growth factors have been used as mobilizing agents of CD34 + cells, such as filgrastim, molgramostim and lenograstim. Filgrastim is the most used agent for this purpose. This study evaluated the results obtained with Filgen JP (Clausen Filgrastim) as the mobilizing agent. (5) Disclosures: Drs. Gabús 
Hematopoietic progenitor cell harvesting
The sources of HPCs used for ASCT in our service were peripheral blood (91.8%), bone marrow and peripheral blood (7.6%) and bone marrow (0.6%). Peripheral blood progenitor cells (PBPC) were harvested by leukapheresis after mobilization with filgrastim or chemotherapy plus filgrastim.
There is a close relation between the infused CD34 + cell number and marrow recovery.
(1,6-10)
Gabús et al. evaluated this relationship in the Hematology Service of Hospital Maciel in 1999 (11) and it was re -A median of two apheresis procedures was needed to obtain the desired number of CD34 + cells. One or two procedures were sufficient in 61.7% of mobilizations, while three aphereses were needed in 18.5% of cases.
-In 9.8% of mobilizations it was not possible to reach adequate counts of CD34 + cells; these patients were rescued with a new mobilization procedure: second mobilization with growth factors, growth factors plus chemotherapy or bone marrow harvesting.
-Among patients who showed complex mobilization, the following frequent characteristics were identified: age above 50 years, multiple myeloma as underlying malignancy and a disease not in a remission state at the time of ASCT.
Aim
The aim of the current retrospective study was to compare stem cell mobilization using different brands of filgrastim. This Service has only used Filgen JP (Clausen Filgrastim) as the mobilizing cytokine since January 2002. Patients mobilized before that date received different brands of filgrastim.
Methods
A descriptive, longitudinal and retrospective study was performed of data from May 1997 to April 2006 of the ASCT program of the Hematology Service of Hospital Maciel. The data sources were as follows:
-Centralized medical records -Data registry forms of the ASCT program -Individual files from the hemobiology laboratory -ASCT discharge summaries One hundred and fifty-seven stimulation-apheresis procedures performed on 149 patients were included in this study (eight double mobilizations). Mobilizations of healthy donors for allogeneic SCT were not evaluated in this work.
Inclusion criteria
The inclusion criterion was stem cell mobilization for ASCT in the Hematology Service of Hospital Maciel with filgrastim as the only mobilizing cytokine between May 1997 and April 2006.
Characteristics of the population
One hundred and fifty-seven mobilizations were divided into two groups, according to the period of time in which the mobilization was performed and therefore the origin of the mobilizing agent. Group A corresponds to patients mobilized with different brands of filgrastim between 1997 and 2001 (n = 76) and Group B corresponds to subjects mobilized with Filgen JP (Clausen Filgrastim) between 2002 and 2006 (n = 81).
Population characteristics (age, gender, underlying malignancy, chemotherapy lines prior to mobilization, previous radiotherapy and disease status at mobilization) are detailed in Table 1 .
Indications for ASCT were as follows: non-Hodgkin lymphoma 66 (42%); multiple myeloma 29 (18.5%); Hodgkin's lymphoma 28 (17.8%); acute myeloblastic leukemia (AML) 23 (14.6%); acute lymphoblastic leukemia (ALL) seven (4.6%) and solid tumors four (2.5%).
Eighty-one stimulation-apheresis procedures (51.6%) were performed in patients whose underlying disorder was in complete remission. In 67 cases (42.7%), corresponding mostly to lymphoproliferative disorders and multiple myeloma, mobilization was achieved in partial remission. Nine patients (5.7%) had progressive disease at the time of mobilization.
As mobilization results are influenced by previous chemotherapy exposure (one, two or more treatment lines) some considerations must be taken into account. Characteristics and intensity of chemotherapy regimens for acute leukemias and chronic lymphoproliferative disorders are not comparable. When considering previous chemotherapy exposure, only chemotherapy lines received by patients with lymphoma, myeloma and solid tumors (n = 127) are shown in Table 1 with AML and ALL patients (n = 30) being excluded in this analysis. In 81 mobilizations, patients had received only one treatment line prior to stimulation with filgrastim. In another 32 mobilizations subjects had received two chemotherapy lines and 11 patients had been exposed to three or more treatment lines. Twenty-four patients (15.3%) had also received radiation treatment at some time before mobilization.
When characteristics of Groups A and B were compared, no statistically significant differences were found regarding gender, ASCT indication, previous chemotherapy lines, exposition to radiotherapy or mobilization strategy.
However the following statistically significant differences (p < 0.05) were found: -Higher age in Group B; -Higher number of subjects in partial remission in Group B; the number of patients in complete remission was significantly higher in Group A (Table 1) .
Mobilization protocol
The mobilization protocol consists on filgrastim (10 mcg/Kg/day subcutaneously) divided in two daily doses during five consecutive days. If the number of CD34 + cells in peripheral blood on the fifth day is above 10 cells/mm 3 , harvesting by apheresis is initiated. If this number is not reached, stimulation is continued but increasing the dose of filgrastim and maintaining it until reaching the desired count for harvesting.
The use of chemotherapy together with the growth factors as mobilization strategy is reserved for the following situations:
1. Patients who are expected to have difficulty in obtaining CD34 + cells. 2. Patients in whom an additional therapeutic benefit in respect to their underlying disease is expected when receiving a cycle of high dose chemotherapy as mobilization protocol.
3. Failure of filgrastim-based mobilization. In these cases, the dose of filgrastim is 5 mcg/Kg/day and administration is started after chemotherapy is finished (day +1 for high dose cyclophosphamide, day +5 in other chemotherapy protocols).
In case of failure in reaching the adequate count of CD34 + cells in peripheral blood, the patient is withdrawn from the mobilization program and one of the following options must be chosen: repeat the mobilization, bone marrow harvesting, or suspend inclusion in the ASCT program.
In the analyzed population, 85% of mobilizations (134) were performed after treatment with filgrastim and 15% (23) after chemotherapy plus filgrastim.
Apheresis protocol
The apheresis procedures were carried out with a Cobe Spectra apheresis system, with continuous flow and processing four blood volumes at a high flow (120 mL/ minute) requiring variable duration (four to six hours each procedure).
CD34
+ cell count protocol 
Statistical analysis
The non-parametric Mann-Whitney test was used to compare differences, as the clinical parameters had an asymmetric (non-Gaussian) distribution. Four groups were created using a cluster analysis technique (Ward algorithm ascending hierarchical clustering), which ensures a minimum intra-group variance and a maximum inter-group variance. The variables used were: age, administered dose of filgrastim, number of apheresis and harvested CD34 + cells.
Results
Considering all mobilization procedures (157) the mean total dose of filgrastim was 105 mcg/Kg (25-300 mcg/Kg). CD34 + cells in peripheral blood on the fifth day of stimulation were quantified only in 54 mobilization procedures (34%). This lack of data was because this parameter was not systematically evaluated in the first stages of the ASCT program. When CD34 -In eight cases the patients were submitted to a second mobilization with filgrastim (in one of them molgramostim was also used in the second mobilization). Considering both first and second mobilizations, a sufficient number of cells was achieved.
-In one case the patient was re-mobilized with filgrastim associated to chemotherapy; -In one case a bone marrow harvest was performed; So in ten cases an adequate CD34 + cellularity was reached, allowing an autologous transplant. In the other case the patient was included in the allogeneic transplant program.
Considering the 157 mobilization procedures, an average of 4.98 x 10 Figure 1 shows the distribution of number of harvested cells in relation to the filgrastim dose.
When these results are analyzed separately for Groups A and B, no significant differences were seen regarding the number of aphereses and harvested CD34 + cells and number of mobilization failures. Total dose of filgrastim was significantly lower in Group B (Table 2) .
Discussion
The results obtained in this study confirm that stimulation with filgrastim in patients who are candidates to ASCT is a feasible method to obtain sufficient stem cells for an adequate autograft. The results obtained in this analysis confirm those already observed in an earlier study with fewer patients. (5) As in the analyzed period there were two groups of patients differentiated by the source of stimulating cytokine (different brands of filgrastim versus Filgen JP [Clausen Filgrastim]), a comparison between these two groups was carried out. As described, Groups A and B are comparable in terms of gender, underlying disorder, chemotherapy lines, previous exposure to radiotherapy and mobilization strategies. Regarding these variables, the following must be taken into consideration:
a) It is known that in certain disorders, such as multiple myeloma, mobilization is more complicated. Although there were no significant differences in the distribution of diseases in each group, there were more myeloma patients in Group B.
b) No significant differences were found between Groups A and B in terms of previous treatment lines, which means that in none of the groups the patients received a more intense treatment. c) Mobilization with chemotherapy plus filgrastim generally means that the total accumulated dose of filgrastim is higher than in cases in which the mobilization was based exclusively on filgrastim. This is because there exists a postchemotherapy aplasia of variable duration, during which filgrastim is used on a daily basis until marrow recovery.
Given the variables in which significant differences between groups were detected, the following must be noted: a) There is no particular explanation for the difference found in the mean ages of patients in groups. While these groups are separated in time, the age criteria for selecting patients for ASCT were not modified between the two periods of the study. b) Regarding the differences found in disease status at the time of mobilization, in Group B there were more patients that reach mobilization in partial remission compared to Group A. During the first years of the ASCT program, indications for autotransplant covered a wider variety of diseases in first complete remission (particularly lymphoproliferative disorders). Thus, Group B patients present a less favorable state at the time of mobilization; it is still debated whether or not being in remission affects the results of the mobilization-harvesting procedure.
When analyzing the results of mobilizations (Table 2 ) it can be seen that there are no significant differences between groups regarding the number of apheresis needed and the The 157 stimulation-apheresis procedures were divided into four groups using a cluster analysis method that took into account similar behavior to stimulation.
-Cluster 1 (n = 19; 12%), average age of 34 years old and an average dose of filgrastim of 77 mcg/Kg. A median of one apheresis was required and 12.7 x 10 6 CD34 + cells/Kg were harvested.
-Cluster 2 (n = 43; 27.4%), average age of 27 years old. Average administered dose of filgrastim in this group was 89 mcg/Kg. A median of two aphereses was required in this group to achieve desired cellularity with an average harvest of 4. Table 3 details characteristics of each cluster, as well as their distribution within Groups A and B. Clusters 1, 2 and 3 shows a favorable behavior in terms of filgrastim dose, number of required apheresis and harvested cells. Most of these procedures belong to Group B. Subjects in Cluster 4 exhibit the worst performance in terms of filgrastim dose, apheresis number and cellularity and were mostly in Group A. 
Conclusions
Stimulation with filgrastim is an adequate method to obtain stem cells in patients for ASCT.
The retrospective and comparative analysis shows that the origin of the cytokine used as the mobilizing agent is an element to be taken into consideration (among other facts) at the time of evaluating the results of the stem cell mobilizationharvest procedure.
